{"entity":{"id":"european-journal-of-cancer","kind":"journal","name":"European Journal of Cancer","aka":["Eur J Cancer","EJC"],"tldr":"The European Journal of Cancer is the Elsevier journal affiliated with the European Organisation for Research and Treatment of Cancer, publishing phase 2 and 3 trials, EORTC quality-of-life questionnaire work, European guidelines on melanoma and skin cancers, and EUROCARE registry epidemiology. It is the place to look for European trial reports and consensus statements.","summary":"The European Journal of Cancer (Eur J Cancer, EJC) is the European journal for clinical and translational cancer research affiliated with the European Organisation for Research and Treatment of Cancer (EORTC), founded in 1965 and published by Elsevier on a hybrid access model. It publishes phase 2 and 3 trials, EORTC quality-of-life questionnaire development and validation, European interdisciplinary guidelines (for example on melanoma and skin cancers), and registry-based epidemiology from EUROCARE. Its readers are clinical and translational oncologists, and it is notable for melanoma, sarcoma, quality-of-life and European guideline work. Within OnCo it is cited from the Desmoid tumour entry, and it is the place to look for European trial reports and guideline consensus.","asOf":"2026-09-09","links":[{"label":"EORTC","url":"https://www.eortc.org"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["qol-pro","preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.ejcancer.com","issn":"0959-8049","scope":"clinical oncology","access":"hybrid","founded":1965,"matchNames":["European Journal of Cancer","Eur J Cancer","EJC"],"society":"European Organisation for Research and Treatment of Cancer"},"route":"/journals/european-journal-of-cancer/","neighbours":{"collection":[{"id":"pubmed-europepmc","kind":"collection","name":"PubMed & Europe PMC","route":"/collections/pubmed-europepmc/"}],"term":[{"id":"preclinical","kind":"term","name":"Preclinical","route":"/terms/preclinical/"},{"id":"qol-pro","kind":"term","name":"Quality of life and patient-reported outcomes (QoL, PRO)","route":"/terms/qol-pro/"}],"person":[{"id":"claudio-lombardo","kind":"person","name":"Claudio Lombardo","route":"/people/claudio-lombardo/"},{"id":"roman-rouzier","kind":"person","name":"Roman Rouzier","route":"/people/roman-rouzier/"},{"id":"sandra-nolte","kind":"person","name":"Sandra Nolte","route":"/people/sandra-nolte/"},{"id":"vasanta-nanduri","kind":"person","name":"Vasanta Nanduri","route":"/people/vasanta-nanduri/"}],"paper":[{"id":"paper-carboplatin-glioblastoma-eur-j-cancer-2017","kind":"paper","name":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report","route":"/key-papers/paper-carboplatin-glioblastoma-eur-j-cancer-2017/"},{"id":"paper-nct05751798-eur-j-cancer-2026","kind":"paper","name":"A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours","route":"/key-papers/paper-nct05751798-eur-j-cancer-2026/"},{"id":"paper-timbergen-eur-j-cancer","kind":"paper","name":"Active surveillance in desmoid-type fibromatosis: A systematic literature review","route":"/key-papers/paper-timbergen-eur-j-cancer/"},{"id":"paper-bien-pancreatoblastoma-expert-european-cooperative-ejc-2011","kind":"paper","name":"Bien 2011: pancreatoblastoma, a report from the European cooperative study group for paediatric rare tumours (EXPeRT)","route":"/key-papers/paper-bien-pancreatoblastoma-expert-european-cooperative-ejc-2011/"},{"id":"paper-laktionov-prolgolimab-domajor-ejc-2025","kind":"paper","name":"DOMAJOR: prolgolimab with chemotherapy first line in advanced non-squamous lung cancer","route":"/key-papers/paper-laktionov-prolgolimab-domajor-ejc-2025/"},{"id":"paper-egfr-gastric-eur-j-cancer-2001","kind":"paper","name":"EGFR and cancer prognosis","route":"/key-papers/paper-egfr-gastric-eur-j-cancer-2001/"},{"id":"paper-clover-eur-j-cancer","kind":"paper","name":"Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019)","route":"/key-papers/paper-clover-eur-j-cancer/"},{"id":"paper-nct04657991-eur-j-cancer-2024","kind":"paper","name":"First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study","route":"/key-papers/paper-nct04657991-eur-j-cancer-2024/"},{"id":"paper-nct05732805-eur-j-cancer-2025","kind":"paper","name":"Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial","route":"/key-papers/paper-nct05732805-eur-j-cancer-2025/"},{"id":"paper-tjulandin-prolgolimab-miraculum-ejc-2021","kind":"paper","name":"MIRACULUM: prolgolimab, the first Russian-developed anti-PD-1 antibody, in advanced melanoma","route":"/key-papers/paper-tjulandin-prolgolimab-miraculum-ejc-2021/"},{"id":"paper-gatta-eur-j-cancer","kind":"paper","name":"Rare cancers are not so rare: the rare cancer burden in Europe","route":"/key-papers/paper-gatta-eur-j-cancer/"},{"id":"paper-peter-thuss-patience-eur-j-cancer-2011","kind":"paper","name":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","route":"/key-papers/paper-peter-thuss-patience-eur-j-cancer-2011/"}],"cancer":[{"id":"desmoid-tumour","kind":"cancer","name":"Desmoid tumour","route":"/cancers/desmoid-tumour/"}]}}